FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241051036> ?p ?o ?g. }

• W4241051036 endingPage "4527" @default.
• W4241051036 startingPage "4527" @default.
• W4241051036 abstract "Abstract HER2 activating mutations are a novel, druggable genomic alteration in metastatic breast cancer (MBC). These HER2 mutations are predominantly found in HER2 gene amplification negative, hormone receptor positive breast cancers. We have previously demonstrated that HER2 mutations can be potently inhibited by the second generation, irreversible pan-HER tyrosine kinase inhibitor, neratinib (Bose et al., Cancer Discovery 2013). Further, we performed a phase II clinical trial to treat HER2 mutated MBC and we found that neratinib monotherapy produced a clinical benefit rate of 31% and progression free survival (PFS) of 16 weeks in a heavily pre-treated patient population (Ma et al., Clin. Can. Res. 2017). A second clinical trial, the SUMMIT trial (Hyman et al., Nature 2018), similarly showed a response rate of 32% and median PFS of 3.5 months for neratinib monotherapy for HER2 mutated, metastatic breast cancer. The objective of the current study is to explore novel combination strategies to improve the efficacy of neratinib in HER2 mutated breast cancer. In order to accelerate progress on testing multiple drug combinations, we developed organoids from two patient-derived xenografts (PDX’s) of HER2 mutated, ER positive metastatic breast cancer from our institution. We found that the ex vivoculture of these patient-derived organoids provides a platform to rapidly perform drug screens and drug combination testing on a scale that cannot be matched by other existing experimental platforms for patient-derived samples. The drug sensitivity of these organoids cultured ex vivo recapitulates the data previously obtained with transfected cell lines and in vivo experiments using PDX’s. Further, multiple drug combinations can be tested on these organoids in just two weeks, which is much shorter than the four to six months required for the corresponding slow-growing ER positive, breast cancer PDX’s that they are derived from. Strong, single agent activity was seen with neratinib, the HER2 antibody drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1), and the chemotherapy drug vinorelbine. Therefore, we tested combinations of neratinib plus the HER2 ADC and neratinib plus vinorelbine on these patient derived organoids. Neratinib plus HER2 ADC showed a strong drug synergy in both HER2 mutated organoids, as judged by the Loewe model of drug synergy. Prior publications suggest that the mechanism of action of neratinib in this combination is by increasing HER2 ubiquitylation and endocytic degradation, which will increase the uptake of the ADC that binds to HER2. We are now performing 384 well drug screens with these HER2 mutated, ER positive metastatic breast cancer organoids, and the results of the screens will be shown in our presentation. Citation Format: Shunqiang Li, Highkin Maureen, Tina M. Primeau, Stephanie L. Pratt, Irmina Diala, Richard E. Cutler, Grace Mann, Alshad S. Lalani, Cynthia X. Ma, Ron Bose. Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4527." @default.
• W4241051036 created "2022-05-12" @default.
• W4241051036 creator A5001373717 @default.
• W4241051036 creator A5007997858 @default.
• W4241051036 creator A5008339153 @default.
• W4241051036 creator A5015397173 @default.
• W4241051036 creator A5030565640 @default.
• W4241051036 creator A5034234418 @default.
• W4241051036 creator A5064072804 @default.
• W4241051036 creator A5065600356 @default.
• W4241051036 creator A5072074183 @default.
• W4241051036 creator A5076883802 @default.
• W4241051036 date "2019-07-01" @default.
• W4241051036 modified "2023-09-27" @default.
• W4241051036 title "Abstract 4527: Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer" @default.
• W4241051036 doi "https://doi.org/10.1158/1538-7445.am2019-4527" @default.
• W4241051036 hasPublicationYear "2019" @default.
• W4241051036 type Work @default.
• W4241051036 citedByCount "0" @default.
• W4241051036 crossrefType "journal-article" @default.
• W4241051036 hasAuthorship W4241051036A5001373717 @default.
• W4241051036 hasAuthorship W4241051036A5007997858 @default.
• W4241051036 hasAuthorship W4241051036A5008339153 @default.
• W4241051036 hasAuthorship W4241051036A5015397173 @default.
• W4241051036 hasAuthorship W4241051036A5030565640 @default.
• W4241051036 hasAuthorship W4241051036A5034234418 @default.
• W4241051036 hasAuthorship W4241051036A5064072804 @default.
• W4241051036 hasAuthorship W4241051036A5065600356 @default.
• W4241051036 hasAuthorship W4241051036A5072074183 @default.
• W4241051036 hasAuthorship W4241051036A5076883802 @default.
• W4241051036 hasBestOaLocation W42410510361 @default.
• W4241051036 hasConcept C121608353 @default.
• W4241051036 hasConcept C126322002 @default.
• W4241051036 hasConcept C143998085 @default.
• W4241051036 hasConcept C150903083 @default.
• W4241051036 hasConcept C207001950 @default.
• W4241051036 hasConcept C26291073 @default.
• W4241051036 hasConcept C2775930923 @default.
• W4241051036 hasConcept C2777329042 @default.
• W4241051036 hasConcept C2779413316 @default.
• W4241051036 hasConcept C2779786085 @default.
• W4241051036 hasConcept C2908647359 @default.
• W4241051036 hasConcept C502942594 @default.
• W4241051036 hasConcept C530470458 @default.
• W4241051036 hasConcept C71924100 @default.
• W4241051036 hasConcept C86803240 @default.
• W4241051036 hasConcept C99454951 @default.
• W4241051036 hasConceptScore W4241051036C121608353 @default.
• W4241051036 hasConceptScore W4241051036C126322002 @default.
• W4241051036 hasConceptScore W4241051036C143998085 @default.
• W4241051036 hasConceptScore W4241051036C150903083 @default.
• W4241051036 hasConceptScore W4241051036C207001950 @default.
• W4241051036 hasConceptScore W4241051036C26291073 @default.
• W4241051036 hasConceptScore W4241051036C2775930923 @default.
• W4241051036 hasConceptScore W4241051036C2777329042 @default.
• W4241051036 hasConceptScore W4241051036C2779413316 @default.
• W4241051036 hasConceptScore W4241051036C2779786085 @default.
• W4241051036 hasConceptScore W4241051036C2908647359 @default.
• W4241051036 hasConceptScore W4241051036C502942594 @default.
• W4241051036 hasConceptScore W4241051036C530470458 @default.
• W4241051036 hasConceptScore W4241051036C71924100 @default.
• W4241051036 hasConceptScore W4241051036C86803240 @default.
• W4241051036 hasConceptScore W4241051036C99454951 @default.
• W4241051036 hasIssue "13_Supplement" @default.
• W4241051036 hasLocation W42410510361 @default.
• W4241051036 hasOpenAccess W4241051036 @default.
• W4241051036 hasPrimaryLocation W42410510361 @default.
• W4241051036 hasRelatedWork W1991018829 @default.
• W4241051036 hasRelatedWork W1994655768 @default.
• W4241051036 hasRelatedWork W2169144202 @default.
• W4241051036 hasRelatedWork W2338354381 @default.
• W4241051036 hasRelatedWork W2420830960 @default.
• W4241051036 hasRelatedWork W2895955393 @default.
• W4241051036 hasRelatedWork W2944980276 @default.
• W4241051036 hasRelatedWork W3083051559 @default.
• W4241051036 hasRelatedWork W3091784252 @default.
• W4241051036 hasRelatedWork W4386804037 @default.
• W4241051036 hasVolume "79" @default.
• W4241051036 isParatext "false" @default.
• W4241051036 isRetracted "false" @default.
• W4241051036 workType "article" @default.